Pancragen is a synthetic tetrapeptide bioregulator targeting pancreatic beta cells. It is studied for its potential to restore insulin production and pancreatic function.
In the literature, Pancragen appears most often in work focused on blood sugar, insulin sensitivity and hormone support. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
Pancragen is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
Albiglutide was a once-weekly GLP-1 receptor agonist developed for the treatment of type 2 diabetes mellitus. It was studied for its ability to improve blood sugar control and provide cardiovascular benefits.
Amylin is a hormone co-secreted with insulin by pancreatic beta cells, playing a role in glucose homeostasis. Researchers investigate its ability to slow gastric emptying, suppress glucagon, and promote satiety.
A gonadotropin studied for testicular function, fertility, and hormonal axis research.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.